Gilead Sciences (NASDAQ:GILD) Given New $105.00 Price Target at Wells Fargo & Company
Gilead Sciences (NASDAQ:GILD – Free Report) had its price objective lifted by Wells Fargo & Company from $100.00 to $105.00 in a report issued on Thursday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. A number of other equities research analysts also recently weighed in on the company. Needham […]
More Stories
Q4 Earnings Estimate for Cavco Industries Issued By Wedbush
Cavco Industries, Inc. (NASDAQ:CVCO – Free Report) – Wedbush decreased their Q4 2026 earnings estimates for shares of Cavco Industries...
FY2026 Earnings Estimate for CVE:AEP Issued By Raymond James
Atlas Engineered Products Ltd. (CVE:AEP – Free Report) – Raymond James decreased their FY2026 EPS estimates for Atlas Engineered Products...
Cormark Issues Positive Estimate for CVE:AEP Earnings
Atlas Engineered Products Ltd. (CVE:AEP – Free Report) – Stock analysts at Cormark increased their Q3 2026 earnings per share...
Q1 Earnings Forecast for 3D Systems Issued By Zacks Research
3D Systems Co. (NYSE:DDD – Free Report) – Analysts at Zacks Research issued their Q1 2027 earnings per share estimates...
Equities Analysts Set Expectations for GT Q3 Earnings
The Goodyear Tire & Rubber Company (NASDAQ:GT – Free Report) – Zacks Research upped their Q3 2025 EPS estimates for...
Analysts Issue Forecasts for RARE FY2025 Earnings
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) – William Blair issued their FY2025 earnings estimates for shares of Ultragenyx Pharmaceutical...